Bio News
Zion Biotech is pursuing global licensing of its Phase 3 drug candidate Votreso, targeting the benign prostatic hyperplasia (BPH) market, which is projected to grow 70% to 33 trillion won by 2035. The candidate, which has entered a U.S. FDA Phase 3 trial, aims to address the unmet need reflected in discontinuation rates of 60% to 90% within 5 years for existing treatments. Based on experience with a total of four Phase 3 trials, the company plans to seek partnerships with multinational pharmaceutical companies.
BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
